We are live on
!
Find out more
Two Sigma Advisers Portfolio holdings
AUM
$51.4B
1-Year Est. Return
31.07%
This Fund
S&P 500
This Quarter
Est. Return
-3.02%
1 Year Est. Return
+31.07%
3 Year Est. Return
+128.94%
5 Year Est. Return
+161.75%
10 Year Est. Return
+607.04%
AUM
$34.5B
AUM Growth
-$708M
(-2%)
Cap. Flow
+$1.23B
Cap. Flow
% of AUM
3.55%
Top 10 Holdings %
Top 10 Hldgs %
13.77%
Holding
2,852
New
233
Increased
919
Reduced
1,343
Closed
332
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Enphase Energy
ENPH
|
+$342M |
| 2 |
Intel
INTC
|
+$276M |
| 3 |
TSMC
TSM
|
+$237M |
| 4 |
Procter & Gamble
PG
|
+$178M |
| 5 |
JPMorgan Chase
JPM
|
+$170M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Netflix
NFLX
|
+$383M |
| 2 |
Occidental Petroleum
OXY
|
+$321M |
| 3 |
PayPal
PYPL
|
+$316M |
| 4 |
S&P Global
SPGI
|
+$145M |
| 5 |
Datadog
DDOG
|
+$133M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.57% |
| 2 | Healthcare | 17.95% |
| 3 | Financials | 9.89% |
| 4 | Industrials | 9.61% |
| 5 | Consumer Discretionary | 7.56% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2251
Protara Therapeutics
TARA
$221M
| $155K | ﹤0.01% |
52,418
-700
| -1% | -$2.37K |
|
2252
Riverview Bancorp
RVSB
$109M
| $154K | ﹤0.01% |
24,300
-100
| -0.4% | -$686 |
|
2253
CorMedix
CRMD
$577M
| $153K | ﹤0.01% |
53,900
-37,200
| -41% | -$155K |
|
2254
Digimarc Corp
DMRC
$145M
| $153K | ﹤0.01% |
11,300
-3,300
| -23% | -$53.4K |
|
2255
Perella Weinberg Partners
PWP
$1.18B
| $153K | ﹤0.01% |
24,100
-1,500
| -6% | -$10.6K |
|
2256
Hycroft Mining Holding Corp
HYMC
$1.87B
| $150K | ﹤0.01% |
24,850
-15,690
| -39% | -$139K |
|
2257
Limbach Holdings
LMB
$864M
| $147K | ﹤0.01% |
19,300
-26,100
| -57% | -$172K |
|
|
SJT
2258
San Juan Basin Royalty Trust
SJT
$117M
| $147K | ﹤0.01% |
+15,600
| New | +$184K |
|
|
ZYNE
2259
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
| $145K | ﹤0.01% |
197,600
+1,500
| +0.8% | +$1.7K |
|
|
SYBX
2260
DELISTED
Synlogic
SYBX
| $144K | ﹤0.01% |
10,120
-133
| -1% | -$2.04K |
|
|
VBIV
2261
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
| $144K | ﹤0.01% |
6,817
-6,010
| -47% | -$162K |
|
2262
UWM Holdings
UWMC
$631M
| $143K | ﹤0.01% |
48,700
+37,400
| +331% | +$138K |
|
2263
EverQuote
EVER
$960M
| $140K | ﹤0.01% |
20,600
-122,500
| -86% | -$1.15M |
|
|
AXDX
2264
DELISTED
Accelerate Diagnostics
AXDX
| $139K | ﹤0.01% |
9,170
+440
| +5% | +$7.28K |
|
2265
LifeMD
LFMD
$186M
| $136K | ﹤0.01% |
68,800
-131,400
| -66% | -$313K |
|
|
TDAY
2266
USA Today Co
TDAY
$1.27B
| $134K | ﹤0.01% |
87,718
-11,000
| -11% | -$26.7K |
|
2267
Urban One Class D
UONEK
$22.6M
| $133K | ﹤0.01% |
3,130
-7,920
| -72% | -$334K |
|
2268
Vivid Seats
SEAT
$88.7M
| $132K | ﹤0.01% |
860
-5
| -0.6% | -$838 |
|
|
PLXP
2269
DELISTED
PLx Pharma Inc. Common Stock
PLXP
| $132K | ﹤0.01% |
202,900
-87,700
| -30% | -$129K |
|
|
AVEO
2270
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
| $132K | ﹤0.01% |
+16,000
| New | +$123K |
|
|
OSG
2271
Octave Specialty Group
OSG
$261M
| $131K | ﹤0.01% |
10,300
-4,300
| -29% | -$57.3K |
|
2272
Superior Group of Companies
SGC
$202M
| $131K | ﹤0.01% |
14,800
-7,400
| -33% | -$106K |
|
2273
Commercial Vehicle Group
CVGI
$152M
| $130K | ﹤0.01% |
28,800
-9,400
| -25% | -$60.2K |
|
2274
Aligos Therapeutics
ALGS
$26.3M
| $129K | ﹤0.01% |
4,700
+212
| +5% | +$7.04K |
|
2275
ProQR Therapeutics
PRQR
$248M
| $129K | ﹤0.01% |
173,300
+117,400
| +210% | +$94.3K |
|
Similar funds
CWM
VRS
FAF
BGIM
CIM
PPFA
Two Sigma Advisers's Q3 2022 Portfolio in Review
As of Q3 2022, Two Sigma Advisers held 2,852 positions worth $34.5B, down 2% from $35.3B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Two Sigma Advisers deployed $1.23B of net new capital in Q3 2022, opening 233 new positions and adding to 919 existing holdings. Its largest new stake was State Street SPDR S&P Biotech ETF: 1,329,800 shares worth $105M.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 24% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Netflix, an estimated $383M trimmed.
- Two Sigma Advisers's largest Q3 2022 buy was State Street SPDR S&P Biotech ETF: 1,329,800 shares worth $105M.
- Two Sigma Advisers added most to Enphase Energy in Q3 2022, an estimated $342M increase.
- Two Sigma Advisers's biggest Q3 2022 reduction was Netflix, cutting an estimated $383M.
- Two Sigma Advisers fully exited S&P Global in Q3 2022, selling an estimated $145M.
- Two Sigma Advisers's ten largest holdings make up 14% of its $34.5B portfolio in Q3 2022.
- Two Sigma Advisers opened 233 new positions and closed 332 in Q3 2022.
- Two Sigma Advisers's portfolio value fell 2% quarter-over-quarter to $34.5B.
Based on Two Sigma Advisers's 13F filing for Q3 2022, filed 14 Nov 2022.